Evaluation of a novel monoclonal antibody mAb109 by immuno-PET/fluorescent imaging for noninvasive lung adenocarcinoma diagnosis

Hua Zhu, Te-li Liu, Chang-hao Liu, Jing Wang, Hong Zhang, Bin Dong, Jing Shen, Chuan-ke Zhao, Zhen-fu Li, Zhen Cheng and Zhi Yang

Monoclonal antibodies are believed to be magic bullets and hold great potential for lots of biological process. About 100 μg of mAb109 was expressed in 5 × 10⁶ cells after 10 days' immunization. ⁶⁴Cu-NOTA-mAb109 was synthesized with the specific activity of 0.74 MBq/μg and high in vitro stability. The binding affinity of ⁶⁴Cu-NOTA-mAb109 in A549 cells was determined to be 29.64 nM. ⁶⁴Cu-NOTA-mAb109 displayed prominent tumor accumulation from 2 h to 60 h p.i. (9.34 ± 0.67 %ID/g). NIRF imaging of Cy5.5-mAb109 showed high accumulation till 9 days p.i., while tumors nearly can not be observed in negative groups, which was confirmed by autoradiography. Immunohistological study confirmed that mAb109 had strong and specific capacity to bind lung adenocarcinoma (concentration to 58 nM). Our study demonstrated mAb109 was a new platform for the development of novel agent for lung adenocarcinoma noninvasive imaging. The resulted ⁶⁴Cu-NOTA-mAb109/Cy5.5-mAb109 show favorable imaging properties/specificity for A549 tumor and high sensitivity to human lung adenocarcinoma tissues.

Keywords: human lung adenocarcinoma; ⁶⁴Cu-NOTA-mAb109; antibody production; positron-emission tomography (PET) imaging; NIRF imaging

INTRODUCTION
Lung cancer is the most common cancer and the leading cause of cancer death in China over the past 20 years [1]. According to data from the National Central Cancer Registry (NCCR), adenocarcinoma has replaced squamous cell carcinoma as the most predominant histological subtype of lung cancer in China, with an incidence of nearly 43.4% among male lung cancer patients in 2012, consistent with the incidence of 40% in the United States [2–4]. Advanced imaging techniques play essential roles in lung cancer diagnosis, staging, and follow-up. 

18F-fluorodeoxyglucose (18F-FDG) PET imaging is conventionally used to perform real-time functional imaging of lung carcinoma. However, the 18F-FDG tracer also has inherent deficiencies due to its limited specificity [5]. For example, 18F-FDG has relatively low uptake in pulmonary adenocarcinoma, which may lead to a false-negative diagnosis. Moreover, 18F-FDG PET has low sensitivity and often misses small malignant lesions between 2 and 5 mm in diameter [6]. To improve the detection sensitivity and specificity of 18F-FDG PET for lung tumors, a large number of tracers have been developed. Due to the benefits of their excellent antigen-specific and binding affinity, monoclonal antibodies are believed to be magic bullets and hold great potential for both tumor imaging and therapy [7].

Peroxiredoxin-1 (Prdx I) is a member of the redox-regulating family peroxiredoxins, which play essential roles in oxidative stress and cell signaling [8]. The Prdx-1 protein is located in the cell membrane and encoded by the Prdx I gene in humans, which is highly expressed in various solid tumors, especially lung tumors [9–11]. Chang et al. [12] confirmed the increased expression of Prdx I by comparing cancer tissues with normal tissues of lung cancer patients and suggested that Prdx I is a useful biomarker for lung cancer. Kim et al. [13] evaluated the expression of Prdx1 and Nrf2 in 90 patients who underwent curative surgical resection and indicated that Prdx I is an independent prognostic factor for lung cancer. Recently, Jiang et al. found that Prdx1 and Prdx4 were preferentially expressed in human lung cancer, including squamous cell carcinoma and adenocarcinoma [14]. These results revealed a statistically significant correlation among the expression of Prdx 1 and lung tumor cell proliferation, recurrence and progression in patients. Therefore, we hypothesize that Prdx 1 holds great potential as an ideal target for lung tumor diagnosis and therapy.

ARTICLE

Acta Pharmacoelogica Sinica (2020) 41:101–109; https://doi.org/10.1038/s41401-019-0294-9

© CPS and SIMM 2019
However, the significance of Prdx I in lung cancer progression and recurrence has not been fully investigated. We previously reported the preliminary results of 111In-labeled mAb109 antibody for the imaging of Prdx I overexpression tumor [15]. PET nuclides are another good choice for acquiring high-quality images. 64Cu is a well-established radionuclide that can be used for PET imaging and targeted radiotherapy of tumors [16]. 64Cu-labeled monoclonal antibodies have a strong binding affinity and specificity for their cognate antigen [17, 18], which can be effectively detected by immuno-PET equipment.

In this study, we describe the production and characterization of a novel antibody, namely mAb109, for use in noninvasive lung tumor diagnosis. A modified method of mAb109 production was developed, and characterization of this antibody was conducted. Then, the mAb109 antibody was used as the primary antibody to confirm its sensitivity to lung tumor. Moreover, a near infrared fluorescence (NIRF) chromophore group, Cy5.5, was conjugated to mAb109 for long-period imaging. In addition, the mAb109 antibody was modified by NOTA and radiolabeled with 64Cu for noninvasive positron-emission tomography (PET) imaging of lung tumors. Finally, immunohistological analysis of 12 lung adenocarcinomic carcinoma tissue samples was performed using mAb109 to evaluate its potential for detecting human lung adenocarcinoma.

**MATERIALS AND METHODS**

Reagents and cell culture

The details of the reagents and cell culture are provided in the Supplemental Materials. S-2-(4-isothiocyanatobenzyl)-1,4,7-triazacyclononane-1,4,7-triacetic acid (p-SCN-Bn-NOTA) was purchased from Macrocyclics, Inc. (Plano, TX, USA). Chelex 100 resin (50–100 mesh) was purchased from Sigma-Aldrich (St. Louis, MI, USA). PD-10 desalting columns were purchased from GE Healthcare (Chicago, IL, USA). PrdxI was acquired from Sinobiological (Beijing, China). All other reaction buffers and chemicals were purchased from Thermo Fisher Scientific (Fisher store in Stanford, USA).

Generation, characterization, NOTA conjugation, and 64Cu radiolabeling of the monoclonal antibody

The human breast carcinoma ZR 75–1 cell line was purchased from ATCC. Female BALB/c mice (6–8 weeks) were intraperitoneally (i.p.) immunized twice with 5 × 10^6 ZR75–1 cells (every 3 weeks). Four days later, splenocytes were harvested. B cells were fused with SP2/0 mouse myeloma cells and cultured in hypoxanthine, aminopterin, and thymidine (HAT medium). The conditioned medium for each clone was screened for anti ZR75-1 mAb presentation using ELISA. For rounds of subcloning/screening, which included lymph cells, ABO red cells, marrow cells, and fibroblast cell negative reactions, were performed. The selected clones, namely, mAb109, were cultured in PRMI-1640 medium under normal cell culture conditions. A total of 5 × 10^6 mAb109 cells were intraperitoneally inoculated into BALB/c mice, and ascites fluid was collected after 10 days. Monoclonal antibodies were purified with CNBr-activated Sepharose4B-protein A chromatography.

The purity of mAb109 was higher than 95% as analyzed by HPLC and sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE; 5% stacking gel, and 8% resolving gel). The molecular weight of mAb109 was evaluated by matrix-assisted laser desorption/ionization (MALDI) analysis. The spectrum was acquired using a positive linear model and analyzed using FlexAnalysis v3.0 software.

mAb109 or a nonspecific IgG antibody was conjugated with NCS-Bz-NOTA at a molar ratio of 1:10 and pH of 8.3 for 4 h as previously reported [15]. The final products (NOTA-mAb109) were purified by PD-10 size-exclusion columns using phosphate-buffered saline (PBS) as the mobile phase to remove unbound NCS-Bz-NOTA. The conjugation of Cy5.5 to mAb109 or a nonspecific IgG antibody was similar (Fig. S3). 64Cu-NOTA-mAb109 and 64Cu-NOTA-IgG were radiosynthesized and purified using reported methods [18].

Cell uptake and binding affinity studies

For the fluorescence microscopy study, A549 cells (1.0 × 10^5) were plated on 35 mm MatTek glass bottom culture dishes. After 24 h, the cells were washed with PBS and then incubated with Cy5.5-mAb109 (55 nM) at 37 °C for 3 h. After incubation, the cells were washed with cold PBS (2 mL × 3). The fluorescence signal of the cells was recorded using an Axiovert 200 M fluorescence microscope (Carl Zeiss Microlmaging, Inc.) equipped with the Cy5.5 filter set (exciter, HQ 650/20 nm; emitter, HQ 695/35 nm).

For the cell uptake study of 64Cu-NOTA-mAb109, A549 cells were plated on 24-well plates (1.0 × 10^5 cells/well) and incubated overnight. Cells were washed twice with serum-free medium and incubated with a radiotracer (2 μCi per well, 74 kBq) in 1 mL of serum-free medium at 37 °C. At 15, 30, 60, and 120 min, cells were washed with cold PBS (0.5 mL × 2) and lysed with 0.5 mL of 0.2 M NaOH.

The cell binding assay for 64Cu-NOTA-mAb109 was conducted with human adenocarcinoma A549 cells. Cells (1 × 10^6 cells/well) were plated on 96-well plates 24 h before the test. Cells were washed with PBS (0.1 mL × 2). Serum-free Dulbecco’s modified Eagle’s medium (0.1 mL) was added to each well. A probe (0.33–66.7 nM final concentration) was added to the wells. To study the binding specificity, increasing amounts of cold, unlabelled mAb109 were added, and the cells were incubated at 37 °C for 4 h. Then, the cells were washed with cold PBS (0.1 mL × 3) and detached with TrypLE-Express (Invitrogen).

The radioactivity of the cells was measured by a γ-counter. The binding affinity and the number of accessible binding sites were estimated by nonlinear regression analysis with a 1-site total binding model using the software package GraphPad Prism (GraphPad Software, Inc.). The concentration at which half of binding was prevented by the blocking agent (IC50) was calculated by nonlinear regression with a 1-site competition model with a variable Hill slope using GraphPad Prism.

Small-animal PET, biodistribution studies, and autoradiography of 64Cu-NOTA-mAb109

All animal studies were conducted under a protocol approved by the Stanford University Institutional Animal Care and Use Committee. A549 tumor models were prepared with a previously reported method. To generate subcutaneous xenografts, 1 × 10^7 A549 cells were suspended in 100 µL of Dulbecco’s phosphate-buffered saline (Invitrogen Life Technologies, Carlsbad, CA) and subcutaneously injected near the left or right forelimb of adult female athymic nude mice (4 week old, Charles River Laboratories, Inc., Cambridge, MA). Imaging was performed when tumors grew to 0.5–1.0 cm in diameter.

PET imaging and image analysis were performed using an R4 PET rodent scanner (Siemens Medical Solutions) as previously reported [17]. After all of the PET scans had been performed, animals were sacrificed and the blood, heart, and other major organs were collected, weighed and measured for radioactivity using a γ-counter (Packard Instruments). The results are presented as %ID/g. Values are expressed as the mean ± SD for four animals. After imaging, sections (10 mm) were generated from snap-frozen tumor tissue harvested from A549 xenografts mice. The sections were stained with hematoxylin and eosin to confirm the histologic status or placed on storage phosphor screens to obtain autoradiography images of the tumors.

Autoradiography analysis was performed as previously reported [18]. Mice were sacrificed at 60 h after micro-PET imaging of 64Cu-NOTA-mAb109, and then, tumor tissues were removed and stored.
at −20 °C for 10 min. The frozen organ was then cut into approximately 1 mm slices and placed onto the surface of a phosphor screen (Amersham Biosciences). The screens were kept in dark for 5 days and were then screened using Typhoon TRIO equipment.

Fluorescent imaging of Cy5.5 conjugates
The synthesis and characterization of the Cy5.5-antibody conjugates are shown in Fig. S3. In vivo fluorescence imaging was performed with an IVIS 200 small-animal imaging system (Xenogen, Alameda, CA). For the positive control experiment, mice (n = 4) were injected with 0.1 nmol of Cy5.5-mAb109 via the tail vein and subjected to optical imaging at various timepoints (from 2 h to 2 weeks). For the blocking experiment, mice (n = 3) were injected with a mixture of 1.5 mg (100 eq excess) of mAb109 and 0.1 nmol of Cy5.5-mAb109. For the negative control experiments, mice (n = 4) were injected with 0.1 nmol of Cy5.5-IgG. IVIS-200 NIR fluorescent images were acquired using a 3-s exposure time, f/stop = 4, and binning = 4. The tumor-targeting efficacy of modified Cy5.5-mAb109 was also evaluated by static small-animal NIRF scans of mice bearing human lung cancer A549.

Immunohistological study of human lung tumor tissues
All specimens were collected during surgery after obtaining written informed consent from patients, and their use for immunohistochemical staining was approved by the Ethics Committee of Peking University Cancer Hospital, China. Lung tumor specimens were surgically removed from patients, and their classification was determined by two or more pathologists. Immunohistochemistry analysis of each sample was performed as previously described using mAb109 as the primary antibody. Immunostaining was performed using the PV-9000 (2-step plus®Poly-HRP AntiMouse/Rabbit IgG detection system) protocol. The intensity of staining was graded as follows: 0, no signal; 1, weak staining; 2, moderate staining; and 3, strong staining.

Statistical analysis
Statistical analysis was performed using Student’s t test for unpaired data. The 95% confidence level was chosen to determine significance between groups, with a P value less than 0.05 being significantly different.

RESULTS
Chemistry and radiochemistry
Antibody production: To generate a high level of the anti-human mAb109 monoclonal antibody, as shown in Fig. 1a, we adopted a fast immunization approach that consisted of preparing cell hybridomas from B cells harvested from the popliteal lymph nodes of mice immunized with the human breast cancer ZR75-1 cell line. The mAb109 antibody was collected and purified through a PD-10 desalting size-exclusion column (GE Healthcare Life Sciences) (Exclusion limit, 5000 Da) using phosphate-buffered saline (PBS) as the mobile phase before modification through a PD-10 column. To radiolabel mAb109 for PET imaging using 64Cu (T1/2 = 12.7 h) as the radionuclide, mAb109 was conjugated to the bifunctional chelator NCS-Bz-NOTA using standard coupling chemistry at a high yield (>60%), radiochemical purity (>95%) (Fig. S1), and specific activity (~0.74–1.48 MBq/μg). The contrast tracer 64Cu-NOTA-IgG was prepared using the same process.

Cell uptake of 64Cu-NOTA-mAb in A549 cells increased over time. 64Cu-NOTA-mAb109 with excess mAb109 and 64Cu-NOTA-IgG had a similar uptake in A549 cells (Fig. 2b). The cell uptake values of 64Cu-NOTA-mAb109 at 15, 30, 60, and 120 min and 37 °C were 3.04% ± 0.34%, 3.78% ± 0.27%, 4.65% ± 0.28%, and 6.77% ± 0.09%, respectively. In the block groups, the cell uptake values were 1.95% ± 0.33% and 2.33% ± 0.30% at 60 and 120 min, respectively. A threefold greater accumulation of the probe occurred in cells incubated at 37 °C compared with the block group, indicating that cell surface binding could be significantly inhibited by the presence of excess mAb109 (P < 0.001).

The affinity of 64Cu-NOTA-mAb109 was tested by binding to A549 cells. Competition binding and saturation studies demonstrated that 64Cu-NOTA-mAb109 specifically bound to A549 cells with nanomolar affinity. The Bmax value was 354 fmol/6000 A549 cells. The affinity of 64Cu-NOTA-mAb109 was 29.6 nM, which was tested by a one-site saturation binding assay (Fig. 2c). As shown in Fig. 2d, blocking the specific binding of 64Cu-NOTA-mAb109 to its receptor by adding serial increasing amounts of cold, unlabeled mAb109 indicated that it had a good specificity of 10.6 mmol (Log(1/IC50)).

Micro-PET/CT imaging and biodistribution study
The tumor-targeting efficacy of 64Cu-NOTA-mAb109 was evaluated by static micro-PET/CT scanning in human adenocarcinoma A549 tumor-bearing mice. Representative decay-corrected coronal PET/CT images obtained at different time points are shown in Fig. 3. Blocking experiments were also conducted using 100 μg of cold mAb109 coincubated with 64Cu-NOTA-mAb109. 64Cu-NOTA-IgG was selected as the negative control for a side-by-side comparison, and these results are shown in Fig. S2. As early as 4 h after administration, tracer uptake in the A549 xenografts was discernible. A549 tumors were clearly visualized in the 64Cu-NOTA-mAb109 group 24 h after injection, with a good tumor-to-background contrast at late time points. Coronal PET images intersecting the tumor showed excellent delineation of the tumor mass with a high tumor/background contrast. In vivo micro-PET images also demonstrated significantly higher (P < 0.05) tumor accumulation (ROI analysis showed it up to 9.5 %ID/g) than that in the blocked and 64Cu-NOTA-IgG groups.

To further validate the PET quantification, the biodistribution by direct tissue sampling was determined after micro-PET/CT imaging at 60 h after injection (Fig. 3a). The biodistribution study revealed that 64Cu-NOTA-mAb109 displayed prominent tumor accumulation from 4 to 60 h after injection (9.34 ± 0.67 %ID/g). At the same time, tumor uptake in the blocking and 64Cu-NOTA-IgG groups was 2.29 ± 0.47 and 2.68 ± 0.69 %ID/g, respectively. By contrast, uptake in other normal organs did not show a significant difference between the 64Cu-DOTA-mAb109 and blocking groups (Fig. 3b1). Moreover, 64Cu-NOTA-mAb109 exhibited the highest tumor-to-lung ratio (3.7) compared with those of the blocking and 64Cu-NOTA-IgG groups (1.0) at 60 h after injection (Fig. 3b2) (P < 0.05). The biodistribution results were consistent with the micro-PET/CT quantification.

Micro-PET/CT imaging demonstrated the effectiveness of 64Cu-NOTA-mAb109 as a noninvasive imaging agent for the detection of human lung adenocarcinoma A549 tumors in vivo. As shown in Fig. 3c, autoradiography of the 64Cu antibody also confirmed this finding. 64Cu-NOTA-mAb109 had an obliviously higher accumulation in A549 tumors than the blocked and 64Cu-NOTA-IgG groups.
Fig. 1  Expression, purification of and characterization of mAb109. a Schematic representation of mAb109 production process. b Reduced and nonreduced SDS-PAGE (8%) analysis of purified mAb109. Molecular weight markers are shown on right. c MALDI-TOF analysis of purified mAb109 antibody. d Western blots of Prdx1 in A549 tumor cells.

Fig. 2  Evaluation of mAb109 antibody. a Cell uptake of Cy5.5-mAb109 (55 nM) in A549 cells at 37 °C. a1 indicates the NIR fluorescent; a2 indicates the hoechst stain of the live cells, and a3 indicates the merge of the fluorescent imaging and cell nuclide. Original magnification ×20 object. b In vitro A549 cell uptake assay. Cell uptake data were expressed as the percentage of the applied radioactivity per total radioactivity. c One site saturation binding study, A549 cells were exposed for 4 h at 37 °C to increasing concentrations of ⁶⁴Cu-NOTA-mAb109. d One site competitive binding study, with the increasing amounts of unlabeled mAb109 were used to block binding of ⁶⁴Cu-NOTA-mAb109 to A549 cells.
Figure 4 shows typical NIR fluorescent images in nude mice bearing A549 tumors after an intravenous injection of 0.2 nmol of Cy5.5-mAb109 without (Fig. 4a) or with (Fig. 4b) excess mAb109 and Cy5.5-IgG (Fig. 4c). The A549 tumors could be clearly visualized by the Cy5.5-mAb109 tracer from 24 h to 16 days. Both the blocked group and the Cy5.5-IgG tracer injected group did not show such persistent and clear NIRF imaging. Moreover, the location of the A549 tumors was evaluated by bioluminescence imaging, as shown in Fig. 4 (right column), 9 days after injection. Quantification analysis of the ROIs was performed, and the tumor-to-normal tissue ratio $T/N$ as a function of time is shown in Fig. 4d. Cy5.5-mAb109 exhibited fast and persistent tumor-targeting properties in vivo. The tumor-to-normal tissue ratio reached 3.2 at 24 h after injection. The T/N ratios remained over 3.0 for the following seven days. The receptor specificity of Cy5.5-mAb109 was verified by mAb109 blocking and Cy5.5-IgG (negative control) fluorescence experiments. Unlabeled mAb109 significantly reduced tumor uptake and tumor contrast after 24 h. Tumor contrast quantified by ROI analysis of images indicated that the T/N value at 24 h p.i. was reduced from 3.2 ± 0.5 to 2.1 ± 0.5 ($P < 0.05$). This phenomenon was also confirmed by the injection of Cy5.5-IgG as a control. Fluorescent imaging of A549 tumors showed a much lower T/N value (1.8 ± 0.3). Liver-to-normal tissue (L/N) quantification analysis of the ROIs was also conducted (Fig. 4e). Both Cy5.5-mAb109 (with or without blocker) and IgG had almost the same L/N ratios at each time point. For example, the L/N ratios of Cy5.5-mAb109 were 2.5 ± 0.3, 1.6 ± 0.3, 1.5 ± 0.0, 1.7 ± 0.2, and 1.5 ± 0.1 compared with 2.3 ± 0.4, 1.8 ± 0.4, 1.7 ± 0.4, 1.6 ± 0.3, 1.4 ± 0.2 for Cy5.5-IgG at 2 h, 1 d, 2 d, 5 d, and 7 d after injection, respectively ($P > 0.5$).

The ex vivo imaging results of Cy5.5-mAb109 in A549 tumor mice at 48 h p.i. are shown in Fig. 5a. Quantitative analysis showed that a large amount of probe was trapped inside tumors and the liver without clearance (Fig. 5c). The tumor-to-normal organ ratios, except the liver ratio, were also high (Fig. 5b). For example, the ratios for tumor-to-blood and tumor-to-kidney were 7.7 ± 0.7 and 4.5 ± 0.4, respectively. Ex vivo NIRF imaging of tumor-bearing mice
demonstrated high uptake and precise localization for tumors of the Cy5.5-mAb tracer at 2 d after administration.

Immunohistological study of human lung adenocarcinoma tissues To further confirm that mAb109 can be used for detection of human lung adenocarcinoma, we performed histological studies of human lung tumor tissues using mAb109 as the primary antibody. Typical IHC staining is shown in Fig. 6; 0.0087 mg/mL (58 nM) mAb109 was selected as the primary antibody, and general peroxidase-anti-mouse/rabbit IgG was selected as the second antibody. Strong stain signals (deep yellow) were clearly observed around the nuclide (blue).

Accordingly, patients with lung adenocarcinoma were selected who had available tissue sections and demographical data (Table 1). The characteristics of a cohort of 12 lung adenocarcinoma tissues are presented in Table 1. Representative immunohistochemistry staining revealed that heavy expression of the mAb109-related receptor was higher in human lung adenocarcinoma tissues. Eleven of 12 tissues expressed some level of mAb109-related receptor. By contrast, 7/12 tissues overexpressed the receptor, reaching a score of 3.

**DISCUSSION**

There is a statistically significant correlation among the expression of Prdx 1 and tumor cell proliferation, recurrence, and progression in lung patients [9-13]. We previously reported that the 111In-labeled mAb109 antibody may be useful for Prx I overexpression tumor imaging [15,16]. Therefore, in this study, a novel antibody, mAb109, was validated, modified, and characterized in a subcutaneous human lung adenocarcinoma A549 xenograft model and human lung tissues to determine its potential for lung cancer diagnosis. This study was performed to establish and validate Prdx1 for noninvasive PET imaging of lung adenocarcinoma. The production of the mAb109 antibody used activated B cells harvested from spleen tissue of ZR 75 cell-immunized BALB/c mice. Over a 99% protein purity and 150 kDa molecular weight of the novel antibody were confirmed by SDS-PAGE and MALDI-TOF analysis, respectively. Western blot analysis showed that the A549 cell line had high Prdx expression (Fig. 1d, e).

To confirm the binding sensitivity of this novel antibody to lung adenocarcinoma tissues, mAb109 was diluted to 580, 145, 97, and 58 nmol (1:50–1:500 dilution) using a primary antibody for IHC staining. As shown in Fig. 7a–c, it was too heavy to determine the
**Fig. 5**  
(a) Ex vivo imaging of tumor and normal tissues of Cy5.5-
mAb109 at 48 h p.i.  
(b) Fluorescence intensity ratios of tumor-to-
normal tissues based on the ROI analysis.  
(c) ROI analysis of fluorescent signal from tumor and normal tissues.  
Error bar was calculated as the standard deviation (n = 3)  

**Table 1.**  
Characteristics of lung adenocarcinoma tissues from Peking University Cancer Hospital for IHC analysis using mAb109 as a primary antibody  

| Patient no. | Age (year) | Gender | Lesion location | Histology | Lesion quantification | Stain score |
|------------|------------|--------|----------------|-----------|----------------------|-------------|
| 1          | 56         | Female | Lobe of left lung | Differentiated adenocarcinoma | SUV max 7.0 | 3 |
| 2          | 53         | Female | Right lung | Middle differentiated adenocarcinoma | SUV max 5.9 | 3 |
| 3          | 60         | Female | Right lower lung | Middle differentiated adenocarcinoma | SUV max 3.5 | 3 |
| 4          | 58         | Female | Right lower lung | Middle differentiated metastatic adenocarcinoma/CFNAKb | SUV max 3.2–4.8 | 3 |
| 5          | 58         | Female | Gastric antrum/body, pulmonary metastasis/cT4N3M1 | Middle differentiated adenocarcinoma | SUV max 2.5–2.3 | 3 |
| 6          | 56         | Male | Left lower lung | High-middle differentiated adenocarcinoma | SUV max 3.3 | 3 |
| 7          | 47         | Male | Left lower lung | Middle differentiated adenocarcinoma/metastatic adenocarcinoma | SUV max 3.3 | 3 |
| 8          | 58         | Male | Right upper lung | Middle differentiated adenocarcinoma | SUV max 3.3 | 3 |
| 9          | 48         | Female | Right lower lung | Middle differentiated adenocarcinoma | SUV max 3.3 | 3 |
| 10         | 71         | Male | Left upper lung | Middle differentiated adenocarcinoma | SUV max 3.3 | 3 |
| 11         | 54         | Female | Left lower lung | Middle differentiated adenocarcinoma | SUV max 3.3 | 3 |
| 12         | 60         | Male | Right lower lung | Middle differentiated adenocarcinoma | SUV max 3.3 | 3 |

**Fig. 6**  
Typical picture of Immunohistochemical (IHC) analysis of human lung adenocarcinoma tissue sample (a) and lymph node sample (b) using 58 nM mAb109 as primary antibody.
The tumor-targeting efficacy of modified mAb109 (0.2 nmol Cy5.5-mAb109) was also evaluated by static small-animal NIRF scans of mice bearing human lung adenocarcinoma cancer A549 tumors. Representative NIRF images are shown in Fig. 4. A549 xenografted tumors can be clearly visualized by the Cy5.5-mAb109 tracer from the surrounding background tissue from 24 h to as long as 16 days. Both the blocked group and the Cy5.5-IgG injected group did not show such persistent and clear NIRF imaging, which indicates the specific binding of this mAb109 antibody. In addition, Fig. 3b2 and Fig. 5b show similar tumor/lung tissue ratios of up to 4.5 from the ex vivo gamma counter-based and fluorescence intensity-based biodistribution studies, indicating that modified mAb109 probes hold great potential for lung cancer imaging due to the high signal to background ratios for both PET and NIRF.

Using IHC staining studies, we isolated a cohort of 12 lung adenocarcinoma tissues from patient-resected solid tumors. Again, mAb109 was used as the primary antibody for this study. As shown in Fig. 7d, markedly stronger mAb109 staining was observed in lung adenocarcinoma tissues compared with adjacent normal tissues. We also confirmed that there was no relationship between the 18F-FDG PET/CT SUV_{max}-based semiquantitative results and mAb109 IHC score. Together, these findings indicate that labeled mAb109 may be useful for detecting lung adenocarcinoma.

The target antigens of the mAb109 antibody are not clearly identified in this study, which is a limitation of this research. However, with the implementation of this modified production approach, we were able to generate stable mAb109 antibody at a high yield. The resulting 64Cu-NOTA-mAb109/Cy5.5-mAb109 showed favorable imaging properties specificity for imaging non-small lung cancer A549 tumors and high sensitivity in tumor cells, mice-based tumor tissues and human lung adenocarcinoma tissues. These results demonstrate that the mAb109 antibody can serve as a new platform for the development of novel agents for lung adenocarcinoma noninvasive imaging.

Herein, we demonstrated for the first time, to our knowledge, that the expression of Prdx1 can be noninvasively evaluated with PET imaging for potential patient selection. In summary, we produced a novel antibody, mAb109, and evaluated the feasibility of using a mAb109-based PET probe for lung cancer imaging. Clinical translation studies of the application of mAb109-based imaging probes for monitoring lung adenocarcinoma still need to be performed.

CONCLUSIONS
Here, we report the production of a new antibody, mAb109, that targets human lung adenocarcinoma. Initially, mAb109 was
radiolabeled with the positron emitter $^{64}\text{Cu}$, and in vitro cell uptake experiments confirmed its binding affinity to A549 cells. Noninvasive uptake of $^{64}\text{Cu}$-NOTA-mAb109/Cy5.5-mAb109 was evaluated by high-resolution micro-PET/C and NIRF images in mice bearing A549 tumor xenografts. An immunohistological study of human lung tissues indicated that mAb109 can be used as a primary antibody to distinguish adenocarcinoma. Over 90% of all lung cancer patients express some level of mAb109-related receptor. With further optimization and development, mAb109-based PET tracers hold potential for use in noninvasive lung adenocarcinoma diagnosis.

ACKNOWLEDGEMENTS
This work was financially supported by National Natural Science Foundation of China projects (Nos. 81671733 and 81571705), Natural Science Foundation of Beijing Municipality (No. 71710000117020), and the Young Top-Notch Talents Team program of Beijing Excellent Talents Funding (No. 2017000021232K33).

AUTHOR CONTRIBUTIONS
HZ, ZC, and ZY designed the experiments. HZ, TLL, CHL, JW, HZ, BD, JS, CKZ, and ZFL performed all the experiments and analyzed the results. HZ, TLL, ZC, and ZY wrote the paper, and all the authors read the paper.

ADDITIONAL INFORMATION
The online version of this article (https://doi.org/10.1038/s41401-019-0294-9) contains supplementary material, which is available to authorized users.

Competing interests: The authors declare no competing interests.

REFERENCES
1. Chen WQ, Zheng RS, Baade PD, Zhang SW, Zeng HM, Bray F, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66:115–32.
2. Zhou CC. Lung cancer molecular epidemiology in China: recent trends. Transl Lung Cancer Res. 2014;3:270–9.
3. Zou XN, Lin DM, Wan X, Chao A, Feng QF, Dai Z, et al. Histological subtypes of lung cancer in Chinese males from 2000 to 2012. Biomed Environ Sci. 2014;27:3–9.
4. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015; 65:5–29.
5. Abouzied MM, Crawford ES, Nabi HA. $^{18}$F-FDG imaging: pitfalls and artifacts. J Nucl Med Technol. 2005;33:145–55.
6. Selnzer M, Hany TF, Wildbrett P, McCormack L, Kadry Z, Clavien PA. Does the novel PET/CT imaging modality impact on the treatment of patients with metastatic colorectal cancer of the liver? Ann Surg. 2004;240:1027–36.
7. Weiner GJ. Building better monoclonal antibody-based therapeutics. Nat Rev Cancer. 2015;15:361–70.
8. Rhee SG, Kang S, Chang TS, Jeong W, Kim K. Peroxiredoxin, a novel family of peroxidases. IUBMB Life. 2001;52:35–41.
9. Lehtonen ST, Svensk AM, Soini Y, Pääkkö P, Hirvikoski P, Kang SW, et al. Peroxiredoxins, a novel protein family in lung cancer. Int J Cancer. 2004;111:514–21.
10. Kim JH, Paul NB, Baek SH, Ramnath N, Liang P, Kim HR, et al. Up-regulation of peroxiredoxin 1 in lung cancer and its implication as a prognostic and therapeutic target. Clin Cancer Res. 2008;14:2326–33.
11. Woo HA, Yim SH, Shin DH, Kang D, Yu DY, Rhee SG. Inactivation of peroxiredoxin I by phosphorylation allows localized H$_2$O$_2$ accumulation for cell signaling. Cell. 2010;140:517–28.
12. Chang JW, Jeon HB, Lee JH, Yoo JS, Chun JS, Kim JH, et al. Augmented expression of peroxiredoxin I in lung cancer. Biochem Biophys Res Commun. 2001;289:507–12.
13. Kim JH, Bogner N, Ramnath P, YooimPark N, Yu J, Park YM. Elevated peroxiredoxin 1, but not NF-E2-related factor 2, is an independent prognostic factor for disease recurrence and reduced survival in stage I non-small cell lung cancer. Clin Cancer Res. 2007;13:3875–82.
14. Jadvar H. FDG PET in prostate cancer. PET Clin. 2009;4:155–61.
15. Lin ZH, Zhang H, Lin XF, Li ZF, Yang Z. Synthesis and evaluation of In-111-DOTA-mAb109 monoclonal antibody for potential SPECT molecular imaging. Acta Chim Sin. 2015;73:36–40.
16. Wadas TJ, Wong EH, Weisman GR, Anderson CJ. Coordinating radiometals of copper, gallium, indium, yttrium, and zirconium for PET and SPECT imaging of disease. Chem Rev. 2010;110:2858–902.
17. Wu YM, Zhu H, Zhang B, Liu F, Chen JX, Wang YF, et al. Synthesis of site-specific radiolabeled antibodies for radioimmunotherapy via genetic code expansion. Bioconjug Chem. 2016;27:2460–8.
18. Miranda E, Nordgren IK, Male AL, Lawrence CE, Hoakwfe F, Cuda F, et al. A cyclic peptide inhibitor of HIF-1 heterodimerization that inhibits hypoxia signaling in cancer cells. J Am Chem Soc. 2013;135:10418–25.